3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
25
Fallopian Tube Neoplasms
21
Multiple Myeloma
18
Carcinoma, Ovarian Epithelial
14
Lymphoma
8
Triple Negative Breast Neoplasms
4
Recurrence
3
Neoplasms, Plasma Cell
3
Hodgkin Disease
3
Prostatic Neoplasms
2
Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Hematologic Neoplasms
2
Burkitt Lymphoma
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Patient Participation
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Interventions
Leucovorin
38
Fluorouracil
36
Oxaliplatin
34
Bevacizumab
34
Irinotecan
32
Cetuximab
23
Capecitabine
18
Panitumumab
14
IFL protocol
7
Folfox protocol
6
Celecoxib
6
Radiotherapy
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gene Expression Profiling
5
regorafenib
4
pembrolizumab
4
dehydroftorafur
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
aflibercept
3
Surgical Procedures, Operative
3
Sorafenib
3
Radiosurgery
3
Ipilimumab
3
Gemcitabine
3
Fentanyl
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colonic Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts